Sample-prep kit maker Proteopure has appointed Ted DeFrank to its board of directors, the company said last week.
DeFrank is president of management consulting company Dalton Enterprises and formerly was president of Pierce Biotechnology, COO of Invitrogen and vice president of operations at Stratagene.
Codon Devices has hired Leda Notchey as its new senior director of marketing; Mario Alfano as its new director of automation; and Tyler Aldredge, who joins the company’s manufacturing operations.
Notchey was formerly a senior executive in the life sciences branch at PerkinElmer; Alfano comes to the company from the discovery group at Millennium Pharmaceuticals; and Aldredge previously worked at the Broad Institute’s DNA sequencing lab as a director of production operations.
Codon Devices, based in Cambridge, Mass., develops gene libraries, engineered cells for pharma research, vaccines, and agricultural products.
The US Senate last week confirmed Andrew von Eschenbach to be the new commissioner of the US Food and Drug Administration.
The Bush appointee, a staunch supporter of genomic technologies in drug discovery, was approved after serving as acting commissioner since September 2005 after former commissioner Lester Crawford resigned.
Von Eschenbach previously headed the National Cancer Institute and was chief academic officer at Houston’s M.D. Anderson Cancer Center, a background that could spell good news for genomics researchers because cancer research is a principal user of genomics technologies.